Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients

Giovanni D’ArenaHematology and Stem Cell Transplantation Unit, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy; Correspondence[email protected]

http://orcid.org/0000-0002-3807-7287

Vittorio SimeonLaboratory of Preclinical and Translational Research, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy;

Luca LaurentiHematology and Stem Cell Transplantation Unit, Catholic University of ‘Sacred Hearth’, Rome, Italy;

Michele CimminielloHematology and Stem Cell Transplantation Unit, ‘S. Carlo’ Hospital, Potenza, Italy;

Idanna InnocentiHematology and Stem Cell Transplantation Unit, Catholic University of ‘Sacred Hearth’, Rome, Italy;

Michele GilioRheumatology Department, ‘S. Carlo’ Hospital, Potenza, Italy; ;Department of Health Sciences, University of Catanzaro ‘Magna Graecia’, Catanzaro, Italy;

Angela PadulaRheumatology Department, ‘S. Carlo’ Hospital, Potenza, Italy;

Maria Luigia VigliottiHematology Unit, ‘S. Sebastiano’ Hospital, Caserta, Italy;

Sonya De LorenzoHematology and Stem Cell Transplantation Unit, ‘A. Tortora’ Hospital, Pagani, Italy;

Giacomo LosetoHematology Unit, IRCCS National Cancer Research Institute ‘Giovanni Paolo II’, Bari, Italy;

Anna PassarelliDepartment of Biomedical Sciences and Human Oncology, ‘Aldo Moro’ University, Bari, Italy;

Matteo Nicola Dario Di MinnoDepartment of Clinical Medicine and Surgery, Regional Service Centre of Coagulation Disorders, ‘Federico II’ University, Naples, Italy; ;Unit of Cell and Molecular Biology in Cardiovascular Diseases, IRCCS Monzino Cardiology Center, Milan, Italy;

http://orcid.org/0000-0001-8059-3819

Marco TucciDepartment of Biomedical Sciences and Human Oncology, ‘Aldo Moro’ University, Bari, Italy;

Vincenzo De FeoDepartment of Pharmacology, University of Salerno, Salerno, Italy;

Fiorella D’AuriaLaboratory of Clinical and Advanced Diagnostics, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy;

Francesco SilvestrisDepartment of Biomedical Sciences and Human Oncology, ‘Aldo Moro’ University, Bari, Italy;

Giovanni Di MinnoDepartment of Clinical Medicine and Surgery, Regional Service Centre of Coagulation Disorders, ‘Federico II’ University, Naples, Italy;

Pellegrino MustoScientific Direction, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero in Vulture, Italy

show all

Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients

ICMJE Forms for Disclosure of Potential Conflicts of Interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date